Ao candidatar-se para um cargo, você pode fornecer informações pessoais, incluindo: https://polyone.referrals.selectminds.com/ mailto:HR@polyone.com • Identificadores e Informações de Contato, como seu nome, data de nascimento, endereço residencial, e-mail particular, número de telefone, Identificadores governamentais (como a sua carta de habilitação e/ou número de identidade nacional); • Dados de Login, incluindo seu endereço de e-mail, nome de usuário e senha quando você inicia sessão para enviar a sua candidatura; • Classificações Protegidas, na medida permitida pela legislação vigente, como seu gênero, raça e origem étnica; • Informações Profissionais ou Relacionadas a Emprego, como seu currículo ou CV, experiência ou histórico profissional, qualificação profissional, cargo para o qual gostaria de candidatar-se, referências profissionais, seu salário atual, bônus, expectativa salarial ou qualquer outra informação que opte por fornecer, incluindo informações relativas a quaisquer candidaturas anteriores que você possa ter-nos enviado ou qualquer experiência prévia de trabalho com a Avient, afiliações ou associações profissionais e preferência de data de início; • Informações Educacionais, como formação acadêmica, seus históricos escolares, histórico acadêmico e de capacitação, sua proficiência em inglês, a qual pode ser necessária para determinados cargos, competências linguísticas e outras competências especiais, informações de certificação; e • Outras informações pessoais que você opte por nos enviar em conexão com a sua candidatura, como dados de contato de referências, informações divulgadas em uma entrevista ou a sua situação pessoal. Data de entrada em vigor: 1º de agosto de 2020 mailto:PRIVACY.OFFICER@POLYONE.COM https://privacyportal.onetrust.com/webform/b25cf7b1-a93a-4d26-8c84-ceda4d0ae91b/e180cbe4-d1b9-49bd-b621-cb5f6a0f42cb mailto:PRIVACY.OFFICER@POLYONE.COM

VERSAFLEX™ HC MEDICAL TUBING GRADES • Improve extrusion rates, achieve high service temperature performance or increase clarity in medical tubing • Traditional and bio- based formulations specifically for biopharmaceutical tubing to meet the needs for weldability and minimize extractables during processing VERSALLOY™ HC SERIES • Obtain better flow in long, thin paths and lower shrink rates versus typical TPVs with our alloys • Color easily and obtain a smooth tactile feel VERSAFLEX™ HC GASKETS & STOPPERS SERIES • Achieve no coring, good puncture and resealability in static stoppers • Meet low COF and low stiction requirements in dynamic seals CL E SERIES • Increase clarity and flexibility in bags, bottles and films • Mitigate risk with plasticizer-free formulations for film extrusion • Deliver excellent odor & O2 barrier performance for film extrusion INDUSTRY BULLETIN TPE HEALTHCARE PRODUCT SELECTOR GUIDE Versaflex™ HC Medical Tubing Grades Versaflex™ HC MT222 Clear 66A 0.88 14 - 334 2.30 629 4.34 898 6.19 430 220 36 ✔ ✔ High clarity, without plasticizersVersaflex™ HC MT224 Clear 75A 0.89 19 - 468 3.23 773 5.33 1360 9.40 530 321 56 ✔ ✔ Versaflex™ HC MT226 Clear 84A 0.88 20 - 606 4.17 885 6.10 1600 11.00 600 433 76 ✔ ✔ Versaflex™ HC MT317 Clear 68A 0.89 17 69 450 3.10 660 4.55 870 6.00 470 221 39 ✔ ✔ Very high service temperature Versaflex™ HC BT218 Natural 67A 0.89 19 69 381 2.60 683 4.70 1186 8.20 608 - - ✔ ✔ Weldable, kink resistant Versalfex™ HC BIO BT218 Natural 70A 0.88 18 58 416 2.87 668 4.60 1190 8.20 630 - - ✔ ✔ Weldable, kink resistant, contains 40% bio-derived content (Gen 1 biomass) Versaflex™ HC Gaskets & Stoppers Series Versaflex™ HC 2110-35N Natural 34A 0.90 19 47 145 1.00 261 1.80 400 2.76 620 97 17 ✔ ✔ Good resealing Versaflex™ HC 2110-43N Natural 43A 0.98 12 46 134 0.92 368 2.54 723 4.98 710 - - ✔ ✔ Good compression set Versaflex™ HC 2110-57B Black 59A 1.01 20 37 369 2.54 558 3.85 537 3.70 350 147 26 ✔ ✔ Low stiction Versaflex™ CL E Series Versaflex™ CL E85 Clear 84A 0.90 20 72 752 5.18 1160 8.00 1550 10.70 450 433 76 ✔ ✔ High clarity, without plasticizers; E95 also offers excellent odor & O2 barrier Versaflex™ CL E90 Clear 90A 0.90 27 73 1000 6.89 1230 8.50 1830 12.60 57 - - ✔ ✔ Versaflex™ CL E95 Clear 95A 0.90 38 71 1680 11.60 1730 11.90 2500 17.20 580 720 126 ✔ ✔ Versaflex™ HC 3810 Series Versaflex™ HC 3810-20N Natural 20A 0.88 16 54 123 0.80 185 1.30 342 2.40 650 - - ✔ - Formulated without animal derivatives, excellent colorability, translucent Versaflex™ HC 3810-30N Natural 30A 0.89 18 58 170 1.20 245 1.70 459 3.20 680 - - ✔ - Versaflex™ HC 3810-40N Natural 40A 0.88 19 59 191 1.30 275 1.90 506 3.50 670 - - ✔ - Versaflex™ HC 3810-50N Natural 50A 0.89 21 61 264 1.80 366 2.50 699 4.80 690 - - ✔ - Versaflex™ HC 3810-60N Natural 60A 0.88 24 65 459 3.20 594 4.10 790 5.40 510 - - ✔ - Versaflex™ HC 3810-70N Natural 70A 0.88 28 67 535 3.70 684 4.70 1000 6.90 570 - - ✔ - Versaflex™ HC 3810-80N Natural 80A 0.88 30 67 689 4.80 869 6.00 1390 9.60 620 - - ✔ - Versaflex™ HC 3810-90N Natural 90A 0.88 27 89 1087 7.50 1350 9.30 1890 13.00 570 - - ✔ - Versalloy™ HC 9210 Series Versalloy™ HC 9210-45N Natural 45A 0.89 19 39 160 1.10 320 2.20 484 3.33 480 100 18 - ✔ Smooth surface aestheticsVersalloy™ HC 9210-55N Natural 53A 0.89 20 44 208 1.44 335 2.31 580 4.00 610 120 21 - ✔ Versalloy™ HC 9210-70N Natural 70A 0.89 23 53 356 2.45 510 3.52 780 5.38 590 180 32 - ✔ Versalloy™ HC 9220 Series Versalloy™ HC 9220-70 Natural 70A 0.95 17 51 453 3.12 - - 643 4.43 265 208 36 ✔ ✔ ExtrudableVersalloy™ HC 9220-80 Natural 80A 0.94 18 59 553 3.67 777 5.36 945 6.52 415 208 36 ✔ ✔ Versalloy™ HC 9220-90 Natural 90A 0.94 25 55 1030 8.13 1350 9.33 1945 13.45 620 400 70 ✔ ✔ Standard Healthcare Grades Versaflex™ G2705N Natural 60A 0.88 - - - - 528 3.64 670 4.62 470 - - ✔ ✔ Natural, high strength Versaflex™ CL 2242 Clear 43A 0.89 23 - 152 1.05 294 2.02 731 5.00 780 124 22 ✔ ✔ High clarity, boilable Versaflex™ CL 2250 Clear 50A 0.89 20 - 220 1.52 337 2.32 827 5.70 770 140 25 ✔ ✔ Versaflex™ OM Series Versaflex™ OM 1040X Natural 42A 0.92 22 - 180 1.24 301 2.08 504 3.47 580 100 18 ✔ ✔ ABS/PC overmoldVersaflex™ OM 3060 Clear 59A 0.90 33 - 420 2.90 360 2.48 500 3.45 480 180 32 ✔ ✔ Versaflex™ OM 8940X-1 Clear 42A 0.91 - - 233 - 311 - 1573 - 1059 - - - - PK, COPE overmold Versaflex™ OM 4052 Natural 56A 1.01 27 - 271 - 557 - 1680 - 670 - - ✔ - Excellent chemical resistance; PK, PC, ABS, PC/ABS overmoldVersaflex™ OM 4063 Natural 54A 1.12 30 - 365 - 580 - 1640 - 670 - - ✔ - Color Hardness Specific Gravity Compression Set @ 23°C Compression Set @ 100°C 100% Modulus 300% Modulus Tensile Strength Elongation Tear Strength ISO 10993 USP VI Special Characteristics ASTM Shore A ASTM/ISO ASTM % ASTM % ASTM psi MPa ASTM psi MPa ASTM psi ISO MPa ASTM % ASTM pll ISO kN/m GENERAL PROPERTIES TENSILE PROPERTIES OTHER For further information on specific grades, review technical data sheets.

10 2021 O U TLO O K Synergies ($ millions) Initial Three-Year Estimate Revised Three-Year Estimate 2021 Expected Realization Administrative $ 18 $ 20 $ 15 Sourcing 24 30 15 Operational 18 25 5 Total Synergies $ 60 $ 75 $ 35 CLARIANT INTEGRATION & COST SYNERGIES UPDATE 12 • Integration going extremely well: synergy target increased from $60 million to $75 million • $5 million of synergies in 2020 and expect to realize $35 million in 2021 • Relentless focus on guiding principles of safety first, employee collaboration and exceeding customer expectations • Future revenue synergies are not part of these estimates and represent additional growth over the long term $86 $103 $0.53 $0.70 ORGANIC GROWTH PROJECTIONS – Q1 13 Sales Adjusted Operating Income $991 $1,090 + 10% Adjusted EPS + 20% + 32% (in millions) (in millions) (1) (1) (1) (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition $308 $360 $1.93 $2.40 ORGANIC GROWTH PROJECTIONS – FULL YEAR 14 Sales Adjusted Operating Income $3,783 $4,100 + 8% Adjusted EPS + 17% + 24% (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (in millions) (in millions) 2020 Pro forma $3,783 $308 Sustainable Solutions 60 11% 24 Healthcare 60 11% 18 Composites 20 10% 10 Growth in Emerging Regions 50 7% 11 Other (GDP growth) 82 5% 11 Sub-total $4,055 7% $382 COVID Response Applications (25) - (11) Outdoor High Performance Applications (15) - (7) Asia Payroll Tax Subsidy (COVID) - - (4) FX Impact 85 - 7 Synergies - - 30 Incentives, Travel, Other Employee Costs - - (37) 2021 Estimated $4,100 8% $360 2021 ORGANIC SALES AND OPERATING INCOME 15 (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (2) COVID Response Applications: facemasks, personal protective equipment Sales Growth Rate Operating Income$ millions (2) CASH FLOW AND LEVERAGE 16 • Asset light business generates significant free cash flow • Cash generation in 2021 partially offset by restructuring activities to capture synergies associated with the Clariant Masterbatch acquisition • Cash flow deployed to M&A, opportunistic share repurchases and balance sheet / leverage reduction 3.5x 2.7x 2.1x 2019PF 2020PF 2021E Net Debt / Adjusted EBITDA (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition ($ millions) 2020 2021E Adjusted EBITDA 382 510 Working Capital: Source / (Use) 116 (30) Cash Taxes (40) (53) Interest Paid (67) (76) CapEx (62) (75) CapEx for Synergy Capture (2) (20) Restructuring for Synergy Capture (11) (25) Other 22 19 Free Cash Flow 338 250 We sell solutions not commodities. Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

We are better together through: Keeping Safety First — PolyOne and Clariant are both ACC Responsible Care® companies, and nothing is more important than the health, safety and well-being of our people. We are Avient. 4 BETTER TOGETHER: POLYONE AND CLARIANT MASTERBATCH Key Data 2020 PF Sales $3.7 billion 2020 PF EBITDA $440 million ($515M w/synergies) 2020E Free Cash Flow $270 million (1) Estimated Pro forma for the acquisition of the Clariant Masterbatch business 87% of EBITDA from specialty applications U.S. & Canada 49% 25% 17% Latin America SEGMENT, END MARKET AND GEOGRAPHY 5 GEOGRAPHY REVENUESEGMENT FINANCIALS 21%Industrial Building & Electrical & END MARKET REVENUE All data reflects 2020 estimate and Pro forma for acquisition of the Clariant Masterbatch business It’s why we win. 11 474 644 925 107 147 212 467 616 858 2014 2018 2020PF R&D / Technical Marketing Sales Commercial Resources + 36% + 37% + 32% + 44% + 44% + 39% Headcount figures are Pro forma for the sale of Designed Structures and Solutions (DSS) and Performance Products and Solutions (PP&S) segments and the acquisition of the Clariant Masterbatch business. 2020PF data as of October 31, 2020.

Aplikując na stanowisko, Kandydat może przekazać Avient swoje dane osobowe, w tym: • Dane identyfikacyjne i kontaktowe, takie jak imię i nazwisko, data urodzenia, adres domowy, osobisty adres e-mail, numer telefonu, dane identyfikacyjne nadane przez organ administracji publicznej (takie jak prawo jazdy i/lub krajowy numer identyfikacyjny [PESEL]); • Dane logowania, w tym adres e-mail, nazwę użytkownika i hasło używane podczas logowania się w celu przesłania podania; • Dane chronione, w zakresie dozwolonym przez obowiązujące prawo, takie jak płeć, rasa i pochodzenie etniczne; • Informacje zawodowe lub związane z zatrudnieniem, takie jak życiorys lub CV, historia zatrudnienia, kwalifikacje zawodowe, informacje o stanowisku, o które Kandydat planuje się ubiegać, referencje dotyczące zatrudnienia, aktualne wynagrodzenie, premie, oczekiwania względem wynagrodzenia lub wszelkie inne informacje, które Kandydat zdecyduje się przekazać, w tym informacje dotyczące wszelkich wcześniejszych podań złożonych w Avient lub wszelkiego poprzedniego doświadczenia zawodowego uzyskanego w Avient, dane o przynależności lub członkostwie w stowarzyszeniach zawodowych oraz preferowaną datę rozpoczęcia zatrudnienia; • Informacje dotyczące odbytej edukacji, takie jak: uzyskane wykształcenie, świadectwa ukończenia szkoły, historia kształcenia i odbytych szkoleń, znajomość języka angielskiego, która może być wymagana na niektórych stanowiskach, język i specjalne umiejętności, informacje o certyfikatach; oraz • Inne dane osobowe, które Kandydat zdecyduje się przekazać Avient w związku ze swoim podaniem, takie jak dane kontaktowe podmiotów wystawiających referencje, informacje ujawnione podczas rozmowy kwalifikacyjnej lub informacje dotyczące osobistej sytuacji Kandydata. Data wejścia w życie: 1 sierpnia 2020 r.

We kept safety first, used service as our timeless diff erentiator, and executed our proven four-pillar strategy. We do this through our safety focus, benefits, and lifestyle programs. Environmental, Health and Safety 4.

PolyOne Corporation Page 4 PolyOne Commodity to Specialty Transformation • Volume driven, commodity producer • Heavily tied to cyclical end markets • Performance largely dependent on non- controlling joint ventures 2000-2005 2006 - 2009 2010 – 2014 2015 and beyond • Steve Newlin appointed, Chairman, President and CEO • New leadership team appointed • Implementation of four pillar strategy • Focus on value based selling, investment in commercial resources and innovation to drive transformation • Substantial EPS growth from $0.13 to all-time high of $1.80 • Shift to faster growing, high margin, less cyclical end markets • Key acquisitions propel current and future growth, as well as margin expansion • Specialty mix expands to 65% of Operating Income – strongest mix of earnings in history • Accelerating growth • Deliver consistent double digit annual EPS growth • Maintain >35% vitality index • Pursue strategic acquisitions that expand specialty offerings and geographic breadth • Invest and grow current and next generation talent PolyOne Corporation Page 5 Building & 10% Electrical & 11% 9% Distribution 28% PP&S Specialty 52% 69% 13% 7% Asia 2014 Revenues: $3.8 Billion End Markets 2014 Revenues: $3.8 Billion PolyOne At A Glance $0.12 $0.27 $0.21 $0.13 $0.68 $0.82 $1.00 $1.31 $1.80 2006 2007 2008 2009 2010 2011 2012 2013 2014 Adjusted EPS PolyOne Corporation Page 6 Old PolyOne *Operating Income excludes corporate charges and special items 2% 34% 43% 62% 65% 66% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2013 2014 YTD 2015 2020 % o f O pe ra tin g In co m e* JV's Performance Products & Solutions Distribution Specialty 80%+ Specialty OI $5M $46M $87M $195M $242M $183M Mix Shift Highlights Specialty Transformation Transformation 2020 Platinum Vision Platinum Vision PolyOne Corporation Page 7 Confirmation of Our Strategy Specialization Globalization Operational Excellence Commercial Excellence Driven by our core values of Collaboration, Innovation and Excellence, we are the world’s premier provider of specialized polymer materials, services and solutions PolyOne Corporation Page 8 2006 YTD 2015 2020 “Where we were” “Where we are” Platinum Vision 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 17.2% 20%+ Global Specialty Engineered Materials 1.1% 15.1% 20%+ Designed Structures & Solutions 1.4% (2012) 3.5% 12 – 14% Performance Products & Solutions 5.5% 8.1% 10 – 12% Distribution 2.6% 6.6% 6.5 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 66% 80%+ 3) ROIC 5.0% 11.9% 15% 4) Adjusted EPS Growth N/A 24 Consecutive Quarters of YOY EPS Growth Double Digit Expansion Proof of Performance & 2020 Goals PolyOne Corporation Page 9 Innovation Drives Earnings Growth *Percentage of Specialty Platform revenue from products introduced in last five years $20 $52 2006 TTM Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* 14% 28% 2006 TTM Specialty Platform Gross Margin % 12% 43% 2006 TTM Specialty Vitality Index Target ≥ 35% TTM 9/30/15 TTM 9/30/15 TTM 9/30/15 PolyOne Corporation Page 10 Innovation Pipeline Potential Prototype Frame Opportunity Scale-up & Test Market Build Business Case Commercial Launch Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 12 4 9 6 1 6 3 7 4 5 6 1 1 7 2 Breakthrough Platform Derivative Number of Projects 12 10 23 19 10 74 Specialty Addressable Market ($ millions) - - $1,150 $1,000 $250 $2,400 PolyOne Corporation Page 11 Lightweighting with Advanced Composites Increasing Healthcare Penetration Innovation Initiatives Expansion in Consumer Markets New Market Development $$$ $$ $ High Temperature Polymers PolyOne Corporation Page 12 Design and Service as a Differentiator Right Material & Color Desired Product Design Appropriate Manufacturing Process Delivering Concept to Commercialization Connecting the Dots with iQ Design Labs and InVisiO Color Design PolyOne Corporation Page 13 Customer First Through World-Class Service Strengthening relationships through:  Providing LSS services to small/medium sized customers • Supporting customers who lack their own formal process improvement initiatives  Providing training in Customer Centric Selling Skills with customers’ sales force PolyOne Corporation Page 14 60% 97% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 Q3 2015 Pension Funding** As of September 30, 2015 Debt Maturities & Pension Funding Net Debt / Adjusted EBITDA** = 2.1x $49 $121 $317 $600 $400 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2018 2020 2023 Debt Maturities As of September 30, 2015 ($ millions) Coupon Rate: 7.500% Variable* 7.375% 5.250% ** includes US-qualified pension plans only *Weighted average rate on revolver was 2.49% as of 9/30/15 **TTM 9/30/2015 PolyOne Corporation Page 15 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return  Expanding our sales, marketing, and technical capabilities  Investing in operational and LSS initiatives  ~75% of capital expenditures fund growth initiatives Organic Growth Acquisitions Share Repurchases Dividends $0.16 $0.20 $0.32 $0.40 $0.48 $0.10 $0.20 $0.30 $0.40 $0.50 2011 2012 2013 2014 2015 2016 Annual Dividend  Targets that expand our: • Specialty offerings • End market presence • Geographic breadth  Synergy opportunities  Adjacent material solutions  Repurchased nearly 2.4 million shares in Q3 2015  Repurchased 14.8 million shares since early 2013  5.2 million shares are available for repurchase under the current authorization $0.24 PolyOne Corporation Page 16 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne? Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Below is a reconciliation of non-GAAP financial measures to the most directly comparable measures calculated and presented in accordance with U.S. Trailing twelve months adjusted gross margin is calculated as follows: Three Months Nine Months Trailing Twelve Months (TTM) Ended (In millions) December 31, 2014 September 30, 2015 September 30, 2015 Gross margin - GAAP $ 152.6 $ 524.6 $ 677.2 Special items in gross margin 15.8 30.0 45.8 Gross margin excluding special items $ 168.4 $ 554.6 $ 723.0 Adjusted EBITDA and net debt to adjusted EBITDA is calculated as follows: Three Months Nine Months Trailing Twelve Months (TTM) Ended (In millions) December 31, 2014 September 30, 2015 September 30, 2015 Income from continuing operations, before income taxes $ (31.2) $ 168.1 $ 136.9 Interest expense, net 15.6 48.5 64.1 Depreciation and amortization 25.0 78.4 103.4 Special items, impact on income from continuing operations before income taxes 80.8 39.8 120.6 Accelerated depreciation included in special items (0.2) (4.6) (4.8) Adjusted EBITDA $ 90.0 $ 330.2 $ 420.2 Short-term portion and current portion of long-term debt $ 61.8 Long-term debt 1,038.0 Less: Cash and cash equivalents (235.7) Net Debt 864.1 Net Debt/TTM Adjusted EBITDA 2.1 Baird Non GAAP Rec Baird - November 10, 2015 POL IR Presentation - November 2015 11.5.2015 - Website ��PolyOne Investor Presentation�RW Baird 2015 Industrial Conference�November 2015�� Forward-Looking Statements Use of Non-GAAP Measures PolyOne Commodity to Specialty Transformation PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Confirmation of Our Strategy Proof of Performance & 2020 Goals Innovation Drives Earnings Growth Innovation Pipeline Potential Innovation Initiatives Design and Service as a Differentiator Customer First Through World-Class Service Debt Maturities & Pension Funding Free Cash Flow and Strong Balance Sheet �Fund Investment / Shareholder Return Why Invest In PolyOne?

In all of its activities, Avient puts high emphasis on environmental protection and safety. This comprehensive EH&S MS systemically identifies and addresses any EHS related risks and is comprised of global standards for safety, health, security, product safety, and environmental protection. As a member of the American Chemistry Council, Avient has also adopted Responsible Care Guiding Principles and the Process Safety Management Practices to guide our efforts in continuous improvement in health and safety performance

CESA™ Block Additives Antiblocking PRODUCT SELECTION GUIDE Unmodified film and sheet can adhere, causing problems of separation. CESA™ Block additives modify the surface characteristics and improve the coefficient of the friction of the sheet or film, preventing self-adhesion.

Additionally, Adjusted EPS excludes the impact of special items and amortization expense associated with intangible assets.2 T RAN S FO R MAT IO NAL OVE RV IE W Avient Protective Materials Dyneema ® RECENT TRANSACTIONS Acquired Divested $1.45 B $0.95 B 4 Distribution UPDATED CAPITAL STRUCTURE & LIQUIDITY • Proceeds from completed sale of Distribution used to pay near-term maturing debt to strengthen balance sheet • Fixed/floating debt ratio of ~55/45 • Proven track record of deleveraging following major acquisitions through strong free cash flow generation • 2022 pro forma net debt/adjusted EBITDA expected to be 3.1x $725 $725 $575 $500 $600 $525 $650 $650 $600 Capital Structure Cash $544 Undrawn Revolver $250 Liquidity $3.15B $2.40B 2030 Notes 2029 Term Loan 2026 Term Loan 2025 Notes 2023 Notes After Dyneema Acquisition After Distribution Divestiture $794M (1) $250M reflects estimated undrawn revolver following the divestiture of Distribution 5 PREVIOUS TRANSACTIONS Performance Solutions Products & $0.8 B COLOR $1.4 B Acquired (2020)Divested (2019) 6 • Acquisition of Clariant Color business significantly expanded presence in healthcare, packaging and consumer end markets • Strength of portfolio – double-digit annual EBITDA growth since acquisition • $75 million of realized synergies anticipated in 2022 • Acquisition completed on July 1, 2020 for $1.45 billion. OPS) 16 Sales Adjusted EBITDA $818 $823 + 1% Adjusted EPS + 8% - 3% (in millions) (in millions) (+ 9% excluding FX) (+ 18% excluding FX) (+ 5% excluding FX) Q3 EBITDA BRIDGE (PRO FORMA TOTAL COMPANY) 17 Price increases more than offset raw material and supply chain impacts $ millions CAI: Price / Mix 68 Inflation (44) SEM: Price / Mix 41 Inflation (26) Net Price Benefit 39 Wage and Energy Inflation (14) Clariant Color Integration Synergies 6 Incentives, Other Employee Costs 14 FX (11) Q3 2022 $137   Adjusted Q3 2021 $ 142 Demand (39) Q3 2022 SEGMENT PERFORMANCE 18 CAI $587 $566 Sales $93 $93 SEM Pro Forma $326 $319 Sales $70 $62 (+ 4% excluding FX) - 4% - 2% (+ 5% excluding FX) Flat (+ 7% excluding FX) - 11% (- 7% excluding FX) $500 $585 $2.60 $2.95 FULL YEAR 2022 GUIDANCE 19 Sales Adjusted EBITDA $3,375 $3,635 Adjusted EPS (in millions) (in millions) 20 SUMMARY • Executed the plans we laid out earlier this year • Completed the Dyneema acquisition and Distribution divestiture amid challenging market conditions • Paid down debt and expect to finish the year modestly levered at 3.1x net debt to 2022 pro forma adjusted EBITDA • Expect $200 million of free cash flow in 2022 • Entering an economic slowdown with a portfolio that is better positioned than ever before • Updated our EPS guidance to $2.60 from continuing operations SEGMENT DATA U.S. & Canada Latin America 2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS 21% Building and END MARKET REVENUE (1) Total company adjusted EBITDA of $585M includes corporate costs. Sales EBITDA Specialty Engineered Materials Color Additives and Inks $585M$3,635M 23 C O L O R , A D D I T I V E S & I N K S 2022 REVENUE | $2 .3 B ILL ION US & Canada Latin America END MARKET REGION 24 33% Building & 1% Energy Figures represent 2022 full year estimates S P E C I A LT Y E N G I N E E R E D M AT E R I A L S 2022 PRO FORMA REVENUE | $1 .3 B ILL ION END MARKET US & Canada 50% REGION 25 Figures represent 2022 full year estimates 19% 8%Industrial 16% Building & 31% 28% 13% Building & 3% 2% Defense (20% of sales) 2022 PROFORMA AVIENT REGIONAL SALES BY END MARKET 29% 13% 17% Building & (35% of sales) 14% Building & 12% US & Canada (40% of sales) 49% Building & LATAM (5% of sales) 3%Telecommunications Figures represent 2022 full year estimates Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.